| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d0fc2b70675ee19bd5fc464f5ae9061 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2018-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b08029b870dcf3d0008d11d4846c54a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1862d6e461a0968559e1a609b43cb6d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_484f85895b3347f81c4a9b39cf042a8c |
| publicationDate |
2019-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190112977-A |
| titleOfInvention |
Use of HSP90AA1 for Treating or Diagnosing NANOG-mediated Diseases |
| abstract |
The present invention relates to the use of HSP90AA1 for the treatment or diagnosis of NANOG-mediated diseases, and more particularly to the use of HSP90AA1 for the treatment and diagnosis of cancer-resistant cancers with increased NANOG expression. The composition for the treatment of NANOG dependent resistant cancer using the novel NANOG / HSP90AA1 immunoresistant molecular axis as a pathological marker according to the present invention, the resistant cancer diagnostic kit or a method for providing information for diagnosis is resistant to chemotherapy such as an anticancer agent or immunotherapy. It is very useful for more precisely and quickly diagnosing and treating cancer in which recurrence or metastasis has occurred after this cancer and chemotherapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023101505-A1 |
| priorityDate |
2018-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |